These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

462 related items for PubMed ID: 28637743

  • 1. Knowledge, attitude and practice of healthcare professionals towards infliximab and insulin glargine biosimilars: result of a UK web-based survey.
    Chapman SR, Fitzpatrick RW, Aladul MI.
    BMJ Open; 2017 Jun 21; 7(6):e016730. PubMed ID: 28637743
    [Abstract] [Full Text] [Related]

  • 2. Healthcare professionals' perceptions and perspectives on biosimilar medicines and the barriers and facilitators to their prescribing in UK: a qualitative study.
    Aladul MI, Fitzpatrick RW, Chapman SR.
    BMJ Open; 2018 Nov 18; 8(11):e023603. PubMed ID: 30455389
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Medical specialists' attitudes to prescribing biosimilars.
    Hemmington A, Dalbeth N, Jarrett P, Fraser AG, Broom R, Browett P, Petrie KJ.
    Pharmacoepidemiol Drug Saf; 2017 May 18; 26(5):570-577. PubMed ID: 28233367
    [Abstract] [Full Text] [Related]

  • 6. Impact of Infliximab and Etanercept Biosimilars on Biological Disease-Modifying Antirheumatic Drugs Utilisation and NHS Budget in the UK.
    Aladul MI, Fitzpatrick RW, Chapman SR.
    BioDrugs; 2017 Dec 18; 31(6):533-544. PubMed ID: 29127626
    [Abstract] [Full Text] [Related]

  • 7. Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015-2018).
    Agirrezabal I, Sánchez-Iriso E, Mandar K, Cabasés JM.
    Diabetes Care; 2020 Aug 18; 43(8):1767-1773. PubMed ID: 32527798
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. [Biosimilars in Inflammatory Bowel Disease (IBD): Experiences and perceptions of german gastroenterologists].
    Bokemeyer B, Dignaß A, Schreiber S.
    Z Gastroenterol; 2017 Apr 18; 55(4):369-374. PubMed ID: 28056484
    [Abstract] [Full Text] [Related]

  • 10. Potential cost-savings from the use of the biosimilars filgrastim, infliximab and insulin glargine in Canada: a retrospective analysis.
    Mansell K, Bhimji H, Eurich D, Mansell H.
    BMC Health Serv Res; 2019 Nov 12; 19(1):827. PubMed ID: 31718624
    [Abstract] [Full Text] [Related]

  • 11. Utilisation Trend of Long-Acting Insulin Analogues including Biosimilars across Europe: Findings and Implications.
    Godman B, Wladysiuk M, McTaggart S, Kurdi A, Allocati E, Jakovljevic M, Kalemeera F, Hoxha I, Nachtnebel A, Sauermann R, Hinteregger M, Marković-Peković V, Tubic B, Petrova G, Tachkov K, Slabý J, Nejezchlebova R, Krulichová IS, Laius O, Selke G, Langner I, Harsanyi A, Inotai A, Jakupi A, Henkuzens S, Garuolienė K, Gulbinovič J, Bonanno PV, Rutkowski J, Ingeberg S, Melien Ø, Mardare I, Fürst J, MacBride-Stewart S, Holmes C, Pontes C, Zara C, Pedrola MT, Hoffmann M, Kourafalos V, Pisana A, Banzi R, Campbell S, Wettermark B.
    Biomed Res Int; 2021 Nov 12; 2021():9996193. PubMed ID: 34676266
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. The effect of new biosimilars in rheumatology and gastroenterology specialities on UK healthcare budgets: Results of a budget impact analysis.
    Aladul MI, Fitzpatrick RW, Chapman SR.
    Res Social Adm Pharm; 2019 Mar 12; 15(3):310-317. PubMed ID: 29807834
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Effectiveness of an intervention strategy in the biosimilar glargine prescription pattern in primary care].
    Saborido-Cansino C, Santos-Ramos B, Carmona-Saucedo C, Rodríguez-Romero MV, González-Martín A, Palma-Amaro A, Rojas-Lucena IM, Almeida-González C, Sánchez-Fidalgo S.
    Aten Primaria; 2019 Mar 12; 51(6):350-358. PubMed ID: 29861115
    [Abstract] [Full Text] [Related]

  • 17. Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naïve patients with spondyloarthritis.
    Lindström U, Glintborg B, Di Giuseppe D, Nordström D, Aarrestad Provan S, Gudbjornsson B, Askling J, Lund Hetland M, Aaltonen K, Krogh NS, Geirsson AJ, Jacobsson LTH.
    RMD Open; 2019 Mar 12; 5(2):e001079. PubMed ID: 31749988
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.
    Baji P, Gulácsi L, Lovász BD, Golovics PA, Brodszky V, Péntek M, Rencz F, Lakatos PL.
    Scand J Gastroenterol; 2016 Jan 12; 51(1):22-7. PubMed ID: 26059967
    [Abstract] [Full Text] [Related]

  • 20. Viewpoint: knowledge and viewpoints on biosimilar monoclonal antibodies among members of the European Crohn's and Colitis Organization.
    Danese S, Fiorino G, Michetti P.
    J Crohns Colitis; 2014 Nov 12; 8(11):1548-50. PubMed ID: 25008477
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.